Abstract
The role of adjuvant radiotherapy to sites of nodal bulky disease in patients with aggressive diffuse large cell lymphoma (DLCL), and stage IV remain undefined. We began a prospective controlled clinical trial to evaluate impact in event free survival (EFS) and overall survival (OS) in a large cohort of patients with a longer follow-up. Between 1989 and 1995; 341 patients with aggressive DLCL and presence of nodal bulky disease (tumor mass > 10 cm) in pathological proven complete response after intensive chemotherapy were randomized to received either radiotherapy (involved fields, 40 Gy) or not. The 5-year EFS and OS in radiated patients were respectively: 82% (95% Confidence interval (CI): 70-89%) and 87% (95% 80-99%), that were statistically significant to control group: 55% (41-64%) (P < 0.001) and 66% (95% CI: 51-73%) (P < 0.01) respectively. Radiotherapy was well tolerated, acute toxicity was mild and until now late toxicity did not appear. The use of adjuvant radiotherapy improve EFS and OS and probably the possibility of cure in patients diffuse large cell lymphoma with worse prognostic factors. Thus, we felt that adjuvant radiotherapy will be considered as part of the initial treatment in this setting of patients.
References
Jan 1, 1992·Critical Reviews in Oncology/hematology·M R MirzaL Specht
Feb 1, 1985·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J M CossetM Tubiana
Nov 15, 1994·International Journal of Radiation Oncology, Biology, Physics·A AvilésJ C Díaz-Maqueo
Jan 1, 1995·International Journal of Radiation Oncology, Biology, Physics·L M FullerJ L Palmer
Aug 1, 1996·American Journal of Hematology·A AvilésJ C Díaz-Maqueo
Apr 1, 1997·Leukemia & Lymphoma·A AvilésE Vásquez
Jun 4, 1998·Cancer·R NairS H Advani
Jul 2, 1998·The New England Journal of Medicine·T P MillerR I Fisher
May 29, 1999·International Journal of Radiation Oncology, Biology, Physics·S S KamathN P Mendenhall
Apr 15, 2000·Oncology·A J FerreriE Villa
Aug 5, 2000·International Journal of Radiation Oncology, Biology, Physics·M OguchiN Hayabuchi
Oct 21, 2000·Acta Oncologica·M Rodriguez-CatarinoH Hagberg
Nov 10, 2000·International Journal of Radiation Oncology, Biology, Physics·P J SchlembachJ D Cox
Feb 13, 2001·British Journal of Cancer·A MessoriG Longo
Feb 13, 2001·International Journal of Radiation Oncology, Biology, Physics·R B WilderJ D Cox
Jun 8, 2001·International Journal of Radiation Oncology, Biology, Physics·R B WilderJ D Cox
Jan 22, 2002·American Journal of Clinical Oncology·M BasaranH Onat
Citations
Aug 4, 2007·Medical Oncology·Agustin AvilésMartha González
Feb 6, 2008·Medical Oncology·Agustin AvilésM Jesús Nambo
Mar 5, 2013·Medical Oncology·Agustin AvilésNatividad Neri
Mar 1, 2007·Nature Clinical Practice. Oncology·Søren M BentzenJacques Bernier
Aug 3, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A DorthC R Kelsey
May 18, 2011·American Journal of Clinical Oncology·Shaojun LinJiade J Lu
Jun 23, 2012·Radiation Oncology·Jennifer A DorthChris R Kelsey
Mar 24, 2006·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Chul S HaMary K Gospodarowicz
Apr 1, 2012·Clinical Journal of Gastroenterology·Junji KohisaYutaka Aoyagi
Sep 29, 2011·Leukemia & Lymphoma·Andrea K Ng, David C Hodgson
Mar 1, 2013·Leukemia & Lymphoma·Zheng ShiMohammad K Khan
Nov 9, 2007·Leukemia & Lymphoma·Andrew Wirth
Jan 20, 2007·British Journal of Haematology·Julio García-SuárezCarmen Burgaleta
Aug 13, 2015·Cancer Metastasis Reviews·Fernando MendesManuel Santos Rosa
Dec 17, 2014·Blood·Laurie H Sehn, Randy D Gascoyne
Feb 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gerhard HeldMichael Pfreundschuh
Jan 18, 2018·Hematology·Agustin AvilèsLuis Silva
Apr 1, 2019·Cancer Reports·Jayant S GodaSridhar Epari